Defilade Capital Management L.P. Boosts Stock Holdings in Globus Medical, Inc. $GMED

Defilade Capital Management L.P. increased its position in shares of Globus Medical, Inc. (NYSE:GMED) by 32.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 354,350 shares of the medical device company’s stock after buying an additional 87,138 shares during the period. Globus Medical accounts for 4.3% of Defilade Capital Management L.P.’s holdings, making the stock its 10th biggest holding. Defilade Capital Management L.P.’s holdings in Globus Medical were worth $30,531,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. NewEdge Advisors LLC lifted its holdings in Globus Medical by 20.0% in the first quarter. NewEdge Advisors LLC now owns 30,540 shares of the medical device company’s stock valued at $2,631,000 after buying an additional 5,091 shares during the period. Glenmede Trust Co. NA grew its holdings in Globus Medical by 22.8% during the 1st quarter. Glenmede Trust Co. NA now owns 225,446 shares of the medical device company’s stock worth $19,424,000 after acquiring an additional 41,801 shares during the period. Summitry LLC grew its holdings in Globus Medical by 2.6% during the 1st quarter. Summitry LLC now owns 8,205 shares of the medical device company’s stock worth $707,000 after acquiring an additional 211 shares during the period. Edgestream Partners L.P. bought a new position in shares of Globus Medical in the 1st quarter worth about $1,895,000. Finally, Janus Henderson Group PLC raised its position in shares of Globus Medical by 4.5% in the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after acquiring an additional 328,217 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Up 0.3%

NYSE GMED opened at $78.99 on Monday. The company has a market cap of $10.72 billion, a price-to-earnings ratio of 18.37, a P/E/G ratio of 1.63 and a beta of 0.95. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40. The business has a 50 day moving average price of $79.53 and a 200-day moving average price of $85.57.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company had revenue of $759.85 million for the quarter, compared to analysts’ expectations of $740.35 million. During the same period last year, the business earned $0.68 EPS. Globus Medical’s quarterly revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts anticipate that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Insiders Place Their Bets

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 18.38% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GMED. Royal Bank Of Canada cut their target price on Globus Medical from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Piper Sandler lowered their target price on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a report on Monday, June 15th. BMO Capital Markets initiated coverage on Globus Medical in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price target on the stock. Truist Financial cut their price target on Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Thursday, July 16th. Finally, Zacks Research downgraded shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $102.08.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.